Alfuzosin (UroXatral®, Sanofi-Synthelabo) a quinazoline derivative, has well-documented α1-adrenoreceptor antagonist activity. These receptors are present in the smooth muscle located at the bladder base, proximal urethra, prostate and prostatic capsule as well as in vascular and nervous systems. Consequently, alfuzosin has the ability to reduce the tone of these areas, effectively decreasing bladder outlet resistance. A sustained-release formulation of alfuzosin is currently available in Europe and is FDA-approved in the US. The confirmed efficacy, proven bioavailability and good cardiovascular safety profile support the use of this drug for the management of lower urinary tract symptoms secondary to benign prostate hyperplasia (BPH). These findings have been confirmed in a large cohort of patients treated in general practice. Additionally, treatment with alfuzosin has demonstrated a favourable impact on quality of life of patients with BPH.
|Original language||English (US)|
|Number of pages||7|
|Journal||Expert Opinion on Pharmacotherapy|
|State||Published - Nov 2003|
- Benign prostate hyperplasia
ASJC Scopus subject areas
- Pharmacology (medical)